5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation

American Journal of Psychiatry

Volumn 155, Issue 7, 1998, Pages 921-928

  Kapur, Shitij ^a,b   Zipursky, Robert B ^a   Remington, Gary ^a   Jones, Corey ^a   Dasilva, Jean ^a   Wilson, Alan A ^a   Houle, Sylvain ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; BENZODIAZEPINE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; PIRENZEPINE; PROLACTIN; PYRIMIDINONE DERIVATIVE; RACLOPRIDE; SALICYLAMIDE DERIVATIVE; SEROTONIN RECEPTOR; SETOPERONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; RIGIDITY; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; BLOOD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ADMINISTRATION; METABOLISM; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; PIRENZEPINE; PROLACTIN; PYRIMIDINONES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SALICYLAMIDES; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0031595586     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.7.921     Document Type: Article

References (43)

1. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-392
2. Meltzer HY: The role of serotonin in schizophrenia and the place of serotonm-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995; 15:25-35
3. Kapur S, Remington G; Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153:466-476
4. Kapur S: A new framework for investigating antipsychotic action in humans: Lessons from PET Imaging. Molecular Psychiatry 1998 (in press)
5. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
6. 2-dopamine receptor occupancy in relation to antipsychotic drug effects-a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33:227-235
7. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153:948-950
8. 2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444-1449
9. 2 occupancy of clozapine? (abstract). J Psychopharmacol 1997; 11:A73
10. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57:PL103-PL107
11. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
12. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine, Neuropsychopharmacology 1996; 14:87-96
13. Beasley CM Jr, Sanger T, Satterlee W, ToIIefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124:159-167
14. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
15. Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154:466-474
16. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
17. 2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology (Berl) 1995; 119:345-348
18. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16:1-7
19. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
20. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale, in Handbook of Psychiatric Rating Scales, 2nd ed. By Lyerly SB. Rockville, Md, National Institute of Mental Health, Clinical Research Branch, 1973, pp 23-25
21. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
22. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
23. 2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990; 47:213-219
24. 2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 1996; 15:562-566
25. 18F] Setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur J Pharmacol 1988; 147:73-82
26. 18F-labeled setoperone. J Neurochem 1990; 54:1744-1754
27. Pazos A, Probst A, Palacios JM: Serotonin receptors in the human brain, IV: autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987; 21:123-139
28. Petit-Taboue MC, Landeau B, Osmont A, Tillet I, Barre L, Baron JC: Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine- 18-setoperone kinetic PET data analysis. J Nucl Med 1996; 37:95-104
29. Mazoyer B: Investigation of the dopamine system with positron emission tomography: general issues in modelling, in Brain Dopaminergic Imaging With Positron Tomography. Edited by Baron JC. Dordrecht, The Netherlands, Kluwer Academic, 1991, pp 64-83
30. 18F]-setoperone PET imaging. Nucl Med Commun 1997; 18:395-399
31. Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PJ, Nohria V, Kerwin RW: Dopamine D-2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine- a I-123 IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996; 124:148-153
32. Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246
33. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B: Positron emission tomography studies on D-2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15:S19-S23
34. Sheitman BB, Lindgren JC, Early J, Sved M; High-dose olanzapine for treatment-refractory schizophrenia (letter). Am J Psychiatry 1997; 154:1626
35. 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl) 1997; 131:148-152
36. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739-745
37. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J: Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 1995; 152:1210-1212
38. Janicak P, Javaid J, Sharma R, Leach A, Easton M, Dowd S, Davis J, Dowd S, Davis J: Haloperidol dose/response relationship-results from a random-assignment, double blind study (abstract). Neuropsychopharmacology 1994; 10:106S
39. Smith RC, Chua JW, Lipetsker B, Bhattacharyya A: Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 1996; 57:460-466
40. Cavallaro R, Colombo C, Smeraldi E: A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Human Psychopharmacology 1995; 10:231-234
41. Lacey RL, Preskorn SH, Jerkovich GS: Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? (letter). Am J Psychiatry 1995; 152:1401
42. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, VanGompel P, Lesage AS, DeLoore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57-73
43. Loch C, Halldin C, Bottlaender M, Swahn CG, Moresco RM, Maziere M, Farde L, Maziere B: Preparation of [Br-76]FLB 457 and [Br-76]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET. Nucl Med Biol 1996; 23: 813-819